Wen-Wu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wen-Wu Li has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Alan Richardson
Keele University
7 shared publications Alan Richardson
Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent ST4 7QB, United Kingdom
6 shared publications- James S. O. McCullagh
University of Oxford
6 shared publications Paul Horrocks
School of Medicine, Keele University, Staffordshire, UK
5 shared publicationsBogang Li
Department of Chemistry, Zhejiang University, Hangzhou 310027, People's Republic of China
4 shared publications- Falko Pieter Drijfhout
Keele University
4 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Applied Microbiology and Biotechnology
Rhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation
Fungi are prolific producers of chemically diverse natural products and biocatalytically active enzymes, yet the biosynthetic and biotransformation potential of many fungal species remains underexplored. This study establishes Rhizopus stolonifer as a promising platform for both natural-product discovery and selective biotransformation of bioactive molecules. Ten cyclic dipeptides (CDPs) and over seventy additional metabolites were tentatively identified using an integrated metabolomics approach combining gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry, and one- and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. Three major CDPs, cyclo(L-Leu-L-Pro), cyclo(L-Ile-L-Pro), and cyclo(L-Phe-L-Pro), were subsequently isolated and characterized, with their stereochemical configurations established. In parallel, R. stolonifer was utilized as a microbial platform for the biotransformation of antimalarial drugs artemisinin and artemether. The resulting derivatives were generated through deoxygenation, site-selective hydroxylation, and structural rearrangement. Time-course NMR analyses provided evidence for the proposed biotransformation pathways. Genome mining revealed six putative non-ribosomal peptide synthetase biosynthetic gene clusters and thirteen cytochrome P450 monooxygenases, suggesting a genetic basis for CDP biosynthesis and artemisinin biotransformation, respectively. These results underscore the dual utility of R. stolonifer as a rich source of CDPs and a versatile biocatalyst for the transformation of artemisinin derivatives. Key points: Rhizopus stolonifer is a rich source of cyclic dipeptides (CDPs). R. stolonifer biotransforms artemisinin and artemether into multiple derivatives. Non-ribosomal peptide synthetase pathways may underpin CDP production.
- 5 November 2026
- Published by Springer Nature in Applied Microbiology and Biotechnology
Open AccessRhizopus stolonifer as a biocatalyst for cyclic dipeptide production and artemisinin/artemether biotransformation
Fungi are prolific producers of chemically diverse natural products and biocatalytically active enzymes, yet the biosynthetic and biotransformation potential of many fungal species remains underexplored. This study establishes Rhizopus stolonifer as a promising platform for both natural-product discovery and selective biotransformation of bioactive molecules. Ten cyclic dipeptides (CDPs) and over seventy additional metabolites were tentatively identified using an integrated metabolomics approach combining gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry, and one- and two-dimensional nuclear magnetic resonance (NMR) spectroscopy. Three major CDPs, cyclo(L-Leu-L-Pro), cyclo(L-Ile-L-Pro), and cyclo(L-Phe-L-Pro), were subsequently isolated and characterized, with their stereochemical configurations established. In parallel, R. stolonifer was utilized as a microbial platform for the biotransformation of antimalarial drugs artemisinin and artemether. The resulting derivatives were generated through deoxygenation, site-selective hydroxylation, and structural rearrangement. Time-course NMR analyses provided evidence for the proposed biotransformation pathways. Genome mining revealed six putative non-ribosomal peptide synthetase biosynthetic gene clusters and thirteen cytochrome P450 monooxygenases, suggesting a genetic basis for CDP biosynthesis and artemisinin biotransformation, respectively. These results underscore the dual utility of R. stolonifer as a rich source of CDPs and a versatile biocatalyst for the transformation of artemisinin derivatives. Key points: Rhizopus stolonifer is a rich source of cyclic dipeptides (CDPs). R. stolonifer biotransforms artemisinin and artemether into multiple derivatives. Non-ribosomal peptide synthetase pathways may underpin CDP production.
- Open Access
- 21 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1824-1832
Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer
Ovarian cancer remains a lethal malignancy due to chemoresistance and toxicity, which limits the dose of chemotherapy that can be used, necessitating the development of more targeted therapies such as antibody-drug conjugates (ADCs). However, conventional ADCs suffer from heterogeneity. This study aimed to develop a stable, homogeneous ADC by utilizing a bifunctional dibromomaleimide (DBM) linker to cross-link antibody cysteine residues via disulfide-bridging. A DBM linker was synthesized from 3,4-dibromofuran-2,5-dione and bound to the cytotoxic agent triptolide. This triptolide payload was then conjugated to trastuzumab via site-specific disulfide rebridging to yield a homogeneous trastuzumab-triptolide conjugate to target human epithelial growth factor receptor 2 (HER2) on ovarian cancer cells. The study evaluated the ADC’s efficacy against SKOV-3 (high HER2 expression) and OVCAR-8 (low HER2 expression) cell lines. The results showed that the ADC was slightly more potent in SKOV-3 cells, yielding lower IC50 values compared to OVCAR-8. Mechanistic studies of the ADC via flow cytometry revealed that the ADC induced significant apoptosis and cell cycle arrest, characterized by a concentration-dependent increase in Caspase-3/7 expression and distinct alterations in cell population distribution. Furthermore, ADC treatment led to a concentration-dependent decrease in HER2 levels in SKOV-3 cells, confirming successful targeting. The study demonstrates that converting conventional maleimides into bifunctional DBM linkers allows the production of a homogeneous ADC via disulfide-bridging. This approach offers a promising strategy for developing potent anticancer therapeutics with improved selectivity for HER2-overexpressing ovarian cancers.
- 21 August 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (9) , 1824-1832
Open AccessDevelopment of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer
Ovarian cancer remains a lethal malignancy due to chemoresistance and toxicity, which limits the dose of chemotherapy that can be used, necessitating the development of more targeted therapies such as antibody-drug conjugates (ADCs). However, conventional ADCs suffer from heterogeneity. This study aimed to develop a stable, homogeneous ADC by utilizing a bifunctional dibromomaleimide (DBM) linker to cross-link antibody cysteine residues via disulfide-bridging. A DBM linker was synthesized from 3,4-dibromofuran-2,5-dione and bound to the cytotoxic agent triptolide. This triptolide payload was then conjugated to trastuzumab via site-specific disulfide rebridging to yield a homogeneous trastuzumab-triptolide conjugate to target human epithelial growth factor receptor 2 (HER2) on ovarian cancer cells. The study evaluated the ADC’s efficacy against SKOV-3 (high HER2 expression) and OVCAR-8 (low HER2 expression) cell lines. The results showed that the ADC was slightly more potent in SKOV-3 cells, yielding lower IC50 values compared to OVCAR-8. Mechanistic studies of the ADC via flow cytometry revealed that the ADC induced significant apoptosis and cell cycle arrest, characterized by a concentration-dependent increase in Caspase-3/7 expression and distinct alterations in cell population distribution. Furthermore, ADC treatment led to a concentration-dependent decrease in HER2 levels in SKOV-3 cells, confirming successful targeting. The study demonstrates that converting conventional maleimides into bifunctional DBM linkers allows the production of a homogeneous ADC via disulfide-bridging. This approach offers a promising strategy for developing potent anticancer therapeutics with improved selectivity for HER2-overexpressing ovarian cancers.
- Open Access
- 23 January 2023
- Published by Elsevier in Scientific African
- Vol. 19
Traditional processing techniques impacted the bioactivities of selected local consumed foods
- 23 January 2023
- Published by Elsevier in Scientific African
- Vol. 19
Open AccessTraditional processing techniques impacted the bioactivities of selected local consumed foods
- 2 December 2022
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 47
Pluripharmacological potential of Mascarene endemic plant leaf extracts
- 2 December 2022
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 47
Pluripharmacological potential of Mascarene endemic plant leaf extracts
- Open Access
- 17 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-13
In vitro and in vivo antimalarial activity and chemical profiling of sugarcane leaves
Saccharum officinarumLinn. (sugarcane, Family-Poaceae) is employed in Ibibio traditional medicine for the treatment of various infections and diseases such as malaria. We This study aims to assess the antiplasmodial effect of the leaf extract and fractions on human malaria parasite (Plasmodium falciparum) in vitro, and rodent malaria parasite (P. berghei) in vivo, and analyse the bioactive components of the active fraction(s). The leaf extract and fractions ofS. officinarumwere prepared and their growth inhibitory effects tested against the chloroquine resistantP. falciparumstrain (Dd2) andP. bergheiinfection in mice. An acute toxicity of the extract was determined. A combination of gas chromatography and liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy was applied for metabolites profiling of crude extract and active fractions. The leaf extract and fractions demonstrated moderate activity againstP. falciparumwith the dichloromethane fraction producing the most potent activity (EC50 = 15.4 µg/mL). The leaf extract (170–510 mg/kg, p.o., LD50 = 1732 mg/kg) and fractions demonstrated significant (p < 0.05–0.001) effect onP. bergheiinfection in prophylactic tests as well as in established infection withn-butanol fractions producing the highest effect. An unusual sulphur-containing compound, dilaurylthiodipropionate, fatty acids, phenolic acids, flavonoid and flavonoid glycoside were identified in the active fractions. These results give credence to the use of sugarcane leaves as malarial remedy locally by confirming the in vitro and in vivo antiplasmodial potential of leaf extract/fractions ofS. officinarum.
- 17 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-13
Open AccessIn vitro and in vivo antimalarial activity and chemical profiling of sugarcane leaves
Saccharum officinarumLinn. (sugarcane, Family-Poaceae) is employed in Ibibio traditional medicine for the treatment of various infections and diseases such as malaria. We This study aims to assess the antiplasmodial effect of the leaf extract and fractions on human malaria parasite (Plasmodium falciparum) in vitro, and rodent malaria parasite (P. berghei) in vivo, and analyse the bioactive components of the active fraction(s). The leaf extract and fractions ofS. officinarumwere prepared and their growth inhibitory effects tested against the chloroquine resistantP. falciparumstrain (Dd2) andP. bergheiinfection in mice. An acute toxicity of the extract was determined. A combination of gas chromatography and liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy was applied for metabolites profiling of crude extract and active fractions. The leaf extract and fractions demonstrated moderate activity againstP. falciparumwith the dichloromethane fraction producing the most potent activity (EC50 = 15.4 µg/mL). The leaf extract (170–510 mg/kg, p.o., LD50 = 1732 mg/kg) and fractions demonstrated significant (p < 0.05–0.001) effect onP. bergheiinfection in prophylactic tests as well as in established infection withn-butanol fractions producing the highest effect. An unusual sulphur-containing compound, dilaurylthiodipropionate, fatty acids, phenolic acids, flavonoid and flavonoid glycoside were identified in the active fractions. These results give credence to the use of sugarcane leaves as malarial remedy locally by confirming the in vitro and in vivo antiplasmodial potential of leaf extract/fractions ofS. officinarum.
- Open Access
- 20 May 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113153
In vivo antihyperglycaemic and antihyperlipidemic activities and chemical constituents of Solanum anomalum
- 20 May 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113153
Open AccessIn vivo antihyperglycaemic and antihyperlipidemic activities and chemical constituents of Solanum anomalum
- Open Access
- 12 April 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (5) , 1749-1762
In Vivo Antibacterial Efficacy of Antimicrobial Peptides Modified Metallic Implants─Systematic Review and Meta-Analysis
Biomaterial-associated infection is difficult to detect and brings consequences that can lead to morbidity and mortality. Bacteria can adhere to the implant surface, grow, and form biofilms. Antimicrobial peptides (AMPs) can target and kill bacterial cells using a plethora of mechanisms of action such as rupturing the cell membrane by creating pores via depolarization with their cationic and amphipathic nature. AMPs can thus be coated onto metal implants to prevent microbial cell adhesion and growth. The aim of this systematic review was to determine the potential clinical applications of AMP-modified implants through in vivo induced infection models. Following a database search recently up to 22 January 2022 using PubMed, Web of Science and Cochrane databases, and abstract/title screening using the PRISMA framework, 24 studies remained, of which 18 were used in the random effects meta-analysis of standardized mean differences (SMD) to get effect sizes. Quality of studies was assessed using SYRCLE’s risk of bias tool. The data from these 18 studies showed that AMPs carry antibacterial effects, and the meta-analysis confirmed the favorited antibacterial efficacy of AMP-coated groups over controls (SMD −1.74, 95%CI [−2.26, −1.26], p < 0.00001). Subgroup analysis showed that the differences in effect size are random, and high heterogeneity values suggested the same. HHC36 and vancomycin were the most common AMPs for surface modification and Staphylococcus aureus, the most tested bacterium in vivo. Covalent binding with polymer brush coating and physical layer-by-layer incorporation of AMPs were recognized as key methods of incorporation to achieve desired densities. The use of fusion peptides seemed admirable to incorporate additional benefits such as osteointegration and wound healing and possibly targeting more microbe strains. Further investigation into the incorporation methods, AMP activity against different bacterial strains, and the number of AMPs used for metal implant surface modification is needed to progress toward potential clinical application.
- 12 April 2022
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (5) , 1749-1762
Open AccessIn Vivo Antibacterial Efficacy of Antimicrobial Peptides Modified Metallic Implants─Systematic Review and Meta-Analysis
Biomaterial-associated infection is difficult to detect and brings consequences that can lead to morbidity and mortality. Bacteria can adhere to the implant surface, grow, and form biofilms. Antimicrobial peptides (AMPs) can target and kill bacterial cells using a plethora of mechanisms of action such as rupturing the cell membrane by creating pores via depolarization with their cationic and amphipathic nature. AMPs can thus be coated onto metal implants to prevent microbial cell adhesion and growth. The aim of this systematic review was to determine the potential clinical applications of AMP-modified implants through in vivo induced infection models. Following a database search recently up to 22 January 2022 using PubMed, Web of Science and Cochrane databases, and abstract/title screening using the PRISMA framework, 24 studies remained, of which 18 were used in the random effects meta-analysis of standardized mean differences (SMD) to get effect sizes. Quality of studies was assessed using SYRCLE’s risk of bias tool. The data from these 18 studies showed that AMPs carry antibacterial effects, and the meta-analysis confirmed the favorited antibacterial efficacy of AMP-coated groups over controls (SMD −1.74, 95%CI [−2.26, −1.26], p < 0.00001). Subgroup analysis showed that the differences in effect size are random, and high heterogeneity values suggested the same. HHC36 and vancomycin were the most common AMPs for surface modification and Staphylococcus aureus, the most tested bacterium in vivo. Covalent binding with polymer brush coating and physical layer-by-layer incorporation of AMPs were recognized as key methods of incorporation to achieve desired densities. The use of fusion peptides seemed admirable to incorporate additional benefits such as osteointegration and wound healing and possibly targeting more microbe strains. Further investigation into the incorporation methods, AMP activity against different bacterial strains, and the number of AMPs used for metal implant surface modification is needed to progress toward potential clinical application.
- Open Access
- 31 March 2022
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 106 (7) , 2433-2444
Biotransformation of artemisinin to a novel derivative via ring rearrangement by Aspergillus niger
Artemisinin is a component part of current frontline medicines for the treatment of malaria. The aim of this study is to make analogues of artemisinin using microbial transformation and evaluate their in vitro antimalarial activity. A panel of microorganisms were screened for biotransformation of artemisinin (1). The biotransformation products were extracted, purified and isolated using silica gel column chromatography and semi-preparative HPLC. Spectroscopic methods including LC-HRMS, GC–MS, FT-IR, 1D and 2D NMR were used to elucidate the structure of the artemisinin metabolites.1H NMR spectroscopy was further used to study the time-course biotransformation. The antiplasmodial activity (IC50) of the biotransformation products of 1 against intraerythrocytic cultures of Plasmodium falciparum were determined using bioluminescence assays. A filamentous fungus Aspergillus niger CICC 2487 was found to possess the best efficiency to convert artemisinin (1) to a novel derivative, 4-methoxy-9,10-dimethyloctahydrofuro-(3,2-i)-isochromen-11(4H)-one (2) via ring rearrangement and further degradation, along with three known derivatives, compound (3), deoxyartemisinin (4) and 3-hydroxy-deoxyartemisinin (5). Kinetic study of the biotransformation of artemisinin indicated the formation of artemisinin G as a key intermediate which could be hydrolyzed and methylated to form the new compound 2. Our study shows that the anti-plasmodial potency of compounds 2, 3, 4 and 5 were ablated compared to 1, which attributed to the loss of the unique peroxide bridge in artemisinin (1). This is the first report of microbial degradation and ring rearrangement of artemisinin with subsequent hydrolysis and methoxylation by A.niger. Key points: • Aspergillus niger CICC 2487 was found to be efficient for biotransformation of artemisinin • A novel and unusual artemisinin derivative was isolated and elucidated • The peroxide bridge in artemisinin is crucial for its high antimalarial potency • The pathway of biotransformation involves the formation of artemisinin G as a key intermediate
- 31 March 2022
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 106 (7) , 2433-2444
Open AccessBiotransformation of artemisinin to a novel derivative via ring rearrangement by Aspergillus niger
Artemisinin is a component part of current frontline medicines for the treatment of malaria. The aim of this study is to make analogues of artemisinin using microbial transformation and evaluate their in vitro antimalarial activity. A panel of microorganisms were screened for biotransformation of artemisinin (1). The biotransformation products were extracted, purified and isolated using silica gel column chromatography and semi-preparative HPLC. Spectroscopic methods including LC-HRMS, GC–MS, FT-IR, 1D and 2D NMR were used to elucidate the structure of the artemisinin metabolites.1H NMR spectroscopy was further used to study the time-course biotransformation. The antiplasmodial activity (IC50) of the biotransformation products of 1 against intraerythrocytic cultures of Plasmodium falciparum were determined using bioluminescence assays. A filamentous fungus Aspergillus niger CICC 2487 was found to possess the best efficiency to convert artemisinin (1) to a novel derivative, 4-methoxy-9,10-dimethyloctahydrofuro-(3,2-i)-isochromen-11(4H)-one (2) via ring rearrangement and further degradation, along with three known derivatives, compound (3), deoxyartemisinin (4) and 3-hydroxy-deoxyartemisinin (5). Kinetic study of the biotransformation of artemisinin indicated the formation of artemisinin G as a key intermediate which could be hydrolyzed and methylated to form the new compound 2. Our study shows that the anti-plasmodial potency of compounds 2, 3, 4 and 5 were ablated compared to 1, which attributed to the loss of the unique peroxide bridge in artemisinin (1). This is the first report of microbial degradation and ring rearrangement of artemisinin with subsequent hydrolysis and methoxylation by A.niger. Key points: • Aspergillus niger CICC 2487 was found to be efficient for biotransformation of artemisinin • A novel and unusual artemisinin derivative was isolated and elucidated • The peroxide bridge in artemisinin is crucial for its high antimalarial potency • The pathway of biotransformation involves the formation of artemisinin G as a key intermediate
- Open Access
- 2 March 2022
- Published by Elsevier in Pharmacological Research - Modern Chinese Medicine
- Vol. 3
Sesquiterpene Lactones Modulated DNA Methylation through Inhibition of DNMTs in Ovarian Cancer Cells
- 2 March 2022
- Published by Elsevier in Pharmacological Research - Modern Chinese Medicine
- Vol. 3
Open AccessSesquiterpene Lactones Modulated DNA Methylation through Inhibition of DNMTs in Ovarian Cancer Cells